Updated:
Engrail Therapeutics
Transforming the lives of patients with life-limiting diseases of the nervous system | We are a neuroscience company forging a new direction to reduce the...
Engrail Therapeutics
Transforming the lives of patients with life-limiting diseases of the nervous system | We are a neuroscience company forging a new direction to reduce the enormous burden of diseases that impact the nervous system. At our core, we unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverage our flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization.
General information
Firm type
Asset Manager
Year founded
2019
Location
Region
North America
Country
United States
City
San Diego
Corporate office
12750 High Bluff Drive Suite 190, San Diego, CA 92130, United States
Principals
Vikram Sudarsan
President and Chief Executive Officer
Kimberly Vanover
Chief Scientific Officer
Paul Cayer
Chief Financial Officer
Stephen Cunningham
EVP, Research & Development and Chief Development Officer
Peter Bisgaard
Chairman of the Board
Sector focus
Frequently asked questions
Who leads investment decisions at Engrail Therapeutics?
Engrail is led by CEO Vikram Sudarsan, a neuroscientist and former CEO of Cipla Technologies. The board includes representatives from its venture investors, including Peter Bisgaard (Pivotal Life Sciences), Tiba Aynechi (Norwest Venture Partners), Jasper Bos (Forbion), Heath Lukatch (Red Tree Venture Capital), and Niall O’Donnell (RiverVest). The firm's R&D strategy is overseen by Chief Development Officer Stephen Cunningham, a co-founder (per firm website).
Is Engrail structured as a family office or a venture-backed biotech?
Engrail is structured as a clinical-stage pharmaceutical company, not a family office. It is capitalized by a syndicate of life-science venture firms including Pivotal Life Sciences, Norwest Venture Partners, Forbion, Red Tree Venture Capital, and RiverVest. There is no disclosed family wealth backing the entity (per firm website).
What does Engrail invest in?
Engrail develops therapeutics for neurologic, neuropsychiatric, and neurodevelopmental disorders. Its pipeline includes ENX-102 (generalized anxiety disorder), ENX-104 (dysthymic disorder), ENX-203 (social anxiety disorder), ENX-205 (a neurodevelopmental disorder), and an undisclosed candidate. The firm uses internal discovery and external partnerships to build its pipeline (per firm website).
Does Engrail make direct investments or fund commitments?
Engrail is not an investment firm; it is a drug development company. It does not make fund commitments or direct investments in other companies. Its capital is deployed into R&D for its own pipeline (per firm website).
What investment stages does Engrail target?
Engrail is a clinical-stage company, meaning it targets drug candidates that have advanced from preclinical discovery into human clinical trials. Its active programs are in Phase 2 trials (per firm website).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: